Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

refractory Plasma Cell Neoplasms

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Relapsed or Refractory Multiple Myeloma

Broader topic: Plasma Cell Neoplasms

Source population
Not part of this definition
Disease extent
refractory
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Relapsed or Refractory Multiple Myeloma

    Study evidence for this setting

    7 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00307086 · Registry condition search · Scope: unclear

    Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

    1 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT00536601 · Registry condition search · Scope: unclear

    High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

    4 outcome links · 5 safety-group records · 0 quality-of-life measures

    →

    NCT01008462 · Registry condition search · Scope: unclear

    Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myelo

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT02506959 · Registry condition search · Scope: unclear

    Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

    3 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT03031730 · Registry condition search · Scope: unclear

    Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

    4 outcome links · 5 safety-group records · 0 quality-of-life measures

    →

    NCT03389347 · Registry condition search · Scope: unclear

    High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

    2 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03499808 · Registry condition search · Scope: unclear

    S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice